Testosterone 5-alpha-reductase

| Main Article
| Discussion
| Definition [?]
| Related Articles  [?]
| Bibliography  [?]
| External Links  [?]
| Citable Version  [?]

|
|
|
|
|
|
|
|
|

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

## Contents

* 1 Benign prostatic hypertrophy
* 2 Developmental androgen disorders
* 3 References

In biology, testosterone 5-alpha-reductase is an enzyme that produces dihydrotestosterone from testosterone.

## Benign prostatic hypertrophy[edit]

Inhibitors are finasteride and dutasteride are used to treat benign prostatic hypertrophy. Both of these medications are metaoblized by cytochrome P-450 CYP3A4.Dutasteride may better prevent acute urinary retention rates than finasteride effective according to a cohort study.[1] may better lower dihydrotestosterone.[2] It may also better reduce symptoms in preliminary trial.[3]

## Developmental androgen disorders[edit]

Both testosterone 5-alpha-reductase deficiency and androgen receptor insensitivity involve this enzyme. The differential diagnosis can be difficult. [4]

## References[edit]

1. ↑ Fenter TC, Davis EA, Shah MB, Lin PJ (2008). "Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.". Am J Manag Care 14 (5 Suppl 2): S154-9. PMID 18611089.
2. ↑ Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004). "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.". J Clin Endocrinol Metab 89 (5): 2179-84. PMID 15126539.
3. ↑ Ravish IR, Nerli RB, Amarkhed SS (2007 Jan-Feb). "Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.". Arch Androl 53 (1): 17-20. DOI:10.1080/01485010600888953. PMID 17364459. Research Blogging.
4. ↑ E T George, S Alvi, N K Taylor & T Mushtaq (2009), "Diagnostic Challenges in Androgen Insensitivity Syndrome & 5 Alpha Reductase Deficiency", Endocrine Abstracts 23: P25